In vivo imaging of neurotransmitter systems in neuropsychiatry

[1]  Melvin Lewis.  Child and Adolescent Psychiatry: A Comprehensive Textbook , 2002 .

[2]  A. C. Collins,et al.  Abnormal Regulation of High Affinity Nicotinic Receptors in Subjects with Schizophrenia , 2000, Neuropsychopharmacology.

[3]  M. Pomper,et al.  Radiolabeled neuronal nitric oxide synthase inhibitors: synthesis, in vivo evaluation, and primate PET studies. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  J. Gorman,et al.  Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[5]  J. Seibyl,et al.  Age-related decline in central serotonin transporter availability with [123I]β-CIT SPECT , 2000, Neurobiology of Aging.

[6]  K. Y. Little,et al.  425. Cocaine effects on striatal dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) protein in humans , 2000, Biological Psychiatry.

[7]  V. Haroutunian,et al.  158. Decreased vesicular monoamine transporter density in schizophrenic prefrontal cortex , 2000, Biological Psychiatry.

[8]  A. Alexandrov,et al.  Transcranial Doppler sonography in acute stroke , 2000 .

[9]  P. Gluckman,et al.  Neuroprotective strategies for basal ganglia degeneration: Parkinson’s and Huntington’s diseases , 2000, Progress in Neurobiology.

[10]  Z. Szabo,et al.  Toxicodynamics and long-term toxicity of the recreational drug, 3, 4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'). , 2000, Toxicology letters.

[11]  M E Phelps,et al.  Long‐term methamphetamine‐induced decreases of [11C]WIN 35,428 binding in striatum are reduced by GDNF: PET studies in the vervet monkey , 2000, Synapse.

[12]  J. Krystal,et al.  Dopamine and serotonin transporters in patients with schizophrenia: an imaging study with [123I]β-CIT , 2000, Biological Psychiatry.

[13]  V. Trajković,et al.  Differential regulation of nitric oxide production by increase of intracellular cAMP in murine primary fibroblasts and L929 fibrosarcoma cell line. , 2000, Immunology letters.

[14]  J. O'Donnell,et al.  Effects of Repeated Antidepressant Treatment on Type 4A Phosphodiesterase (PDE4A) in Rat Brain , 2000, Journal of neurochemistry.

[15]  M. Liebowitz,et al.  Low dopamine D(2) receptor binding potential in social phobia. , 2000, The American journal of psychiatry.

[16]  B. Wahrén,et al.  Rolipram suppresses experimental autoimmune neuritis and prevents relapses in Lewis rats , 2000, Neuropharmacology.

[17]  R. Witkamp,et al.  Signal transduction in inflammatory processes, current and future therapeutic targets: A mini review , 2000, The Veterinary quarterly.

[18]  D. Murphy,et al.  Altered neuroendocrine and behavioral responses to m-chlorophenylpiperazine in 3,4-methylenedioxymethamphetamine (MDMA) users , 1999, Psychopharmacology.

[19]  J. Krystal,et al.  [123I]Iomazenil SPECT benzodiazepine receptor imaging in schizophrenia , 1999, Psychiatry Research: Neuroimaging.

[20]  R. Blasberg,et al.  Imaging adenoviral-mediated herpes virus thymidine kinase gene transfer and expression in vivo. , 1999, Cancer research.

[21]  A. Levey,et al.  Dopamine transporters and neuronal injury. , 1999, Trends in pharmacological sciences.

[22]  J. O'Donnell,et al.  Effects of noradrenergic lesions on the development of rolipram-sensitive, low-K(m), cyclic AMP specific phosphodiesterase in rat brain. , 1999, Brain research. Developmental brain research.

[23]  J. Palacios,et al.  Preliminary Evidence for an Involvement of the Cholinergic System in the Sedative Effects of Rolipram in Rats , 1999, Pharmacology Biochemistry and Behavior.

[24]  Roland Martin,et al.  Differential effects of phosphodiesterase type 4-specific inhibition on human autoreactive myelin-specific T cell clones , 1999, Journal of Neuroimmunology.

[25]  M. Laruelle,et al.  Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies , 1999, Journal of psychopharmacology.

[26]  P. Pollak,et al.  The relation of putamen and caudate nucleus 18F-Dopa uptake to motor and cognitive performances in Parkinson’s disease , 1999, Journal of the Neurological Sciences.

[27]  R. Albin,et al.  Striatal presynaptic monoaminergic vesicles are not increased in Tourette’s syndrome , 1999, Neurology.

[28]  A. Alavi,et al.  Potential applications of PET imaging in developing novel cancer therapies. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[29]  Blasberg Rg,et al.  Herpes simplex virus thymidine kinase as a marker/reporter gene for PET imaging of gene therapy. , 1999 .

[30]  V. A. Folcik,et al.  Treatment with BBB022A or rolipram stabilizes the blood-brain barrier in experimental autoimmune encephalomyelitis: an additional mechanism for the therapeutic effect of type IV phosphodiesterase inhibitors , 1999, Journal of Neuroimmunology.

[31]  John Seibyl,et al.  No Evidence of Altered In Vivo Benzodiazepine Receptor Binding in Schizophrenia , 1999, Neuropsychopharmacology.

[32]  U. McCann,et al.  Neuropathology of cocaine abuse , 1999 .

[33]  J. O'Donnell,et al.  Behavioral Effects of Family-Selective Inhibitors of Cyclic Nucleotide Phosphodiesterases , 1999, Pharmacology Biochemistry and Behavior.

[34]  S. Cherry,et al.  Repetitive, non-invasive imaging of the dopamine D2 receptor as a reporter gene in living animals , 1999, Gene Therapy.

[35]  U. Kang,et al.  Vesicular Monoamine Transporter-2 and Aromaticl-Amino Acid Decarboxylase Enhance Dopamine Delivery afterl-3,4-Dihydroxyphenylalanine Administration in Parkinsonian Rats , 1999, The Journal of Neuroscience.

[36]  R. Gainetdinov,et al.  Increased Methamphetamine Neurotoxicity in Heterozygous Vesicular Monoamine Transporter 2 Knock-Out Mice , 1999, The Journal of Neuroscience.

[37]  D. Wong,et al.  Doses of GBR12909 that suppress cocaine self‐administration in non‐human primates substantially occupy dopamine transporters as measured by [11C] WIN35,428 PET scans , 1999, Synapse.

[38]  J. Zubieta,et al.  PET imaging of the dopamine transporter in progressive supranuclear palsy and Parkinson’s disease , 1999, Neurology.

[39]  V L Villemagne,et al.  Loss of D2 Receptor Binding with Age in Rhesus Monkeys: Importance of Correction for Differences in Striatal Size , 1999, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[40]  K A Frey,et al.  Striatal dopaminergic abnormalities in human cocaine users. , 1999, The American journal of psychiatry.

[41]  C. Kornetsky,et al.  The Type IV Phosphodiesterase Inhibitors, Ro 20-1724 and Rolipram, Block the Initiation of Cocaine Self-Administration , 1999, Pharmacology Biochemistry and Behavior.

[42]  J. Connors,et al.  Interventional Neuroradiology: Strategies and Practical Techniques , 1999 .

[43]  M Laruelle,et al.  Alterations of benzodiazepine receptors in type II alcoholic subjects measured with SPECT and [123I]iomazenil. , 1998, The American journal of psychiatry.

[44]  F. Fadda,et al.  Chronic ethanol consumption:from neuroadaptation to neurodegeneration , 1998, Progress in Neurobiology.

[45]  Z. Szabo,et al.  Positron emission tomographic evidence of toxic effect of MDMA (“Ecstasy”) on brain serotonin neurons in human beings , 1998, The Lancet.

[46]  D. Wong,et al.  Reduced Striatal Dopamine Transporter Density in Abstinent Methamphetamine and Methcathinone Users: Evidence from Positron Emission Tomography Studies with [11C]WIN-35,428 , 1998, The Journal of Neuroscience.

[47]  J. Humm,et al.  Imaging herpes virus thymidine kinase gene transfer and expression by positron emission tomography. , 1998, Cancer research.

[48]  R. Kerwin,et al.  5-HT2A receptor blockade in patients with schizophrenia treated with risperidone or clozapine , 1998, British Journal of Psychiatry.

[49]  N. Ilgin.  Functional imaging of neurotransmitter systems in movement disorders. , 1998, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[50]  M. Laruelle.  Imaging dopamine transmission in schizophrenia. A review and meta-analysis. , 1998, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[51]  G. Benedek,et al.  Rolipram, an Antidepressant That Increases the Availability of cAMP, Transiently Enhances Wakefulness in Rats , 1998, Pharmacology Biochemistry and Behavior.

[52]  S. Amara,et al.  Neurotransmitter transporters as molecular targets for addictive drugs. , 1998, Drug and alcohol dependence.

[53]  J. Krystal,et al.  Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. , 1998, The American journal of psychiatry.

[54]  G. Uhl.  Hypothesis: The role of dopaminergic transporters in selective vulnerability of cells in Parkinson's disease , 1998, Annals of neurology.

[55]  P. Hartvig,et al.  Increased synthesis of dopamine in prefrontal cortex and striatum in drug-naive schizophrenic patients studied by use of C11-labelled I-DOPA and positron emission tomography (PET) , 1998, Schizophrenia Research.

[56]  J. Krystal,et al.  507 In vivo evaluation of dopamine synaptic funcflon in untreated schizophrenic patients , 1997, Schizophrenia Research.

[57]  J. Masdeu.  American Academy of Neurology neuroimaging training guidelines , 1997, Neurology.

[58]  J. Masdeu,et al.  American Academy of Neurology guidelines for credentialing in neuroimaging , 1997, Neurology.

[59]  M. Kilbourn.  In vivo radiotracers for vesicular neurotransmitter transporters. , 1997, Nuclear medicine and biology.

[60]  T. Robinson,et al.  Reduced striatal vesicular monoamine transporters after neurotoxic but not after behaviorally-sensitizing doses of methamphetamine. , 1997, European journal of pharmacology.

[61]  Marc Laruelle,et al.  Imaging D2 Receptor Occupancy by Endogenous Dopamine in Humans , 1997, Neuropsychopharmacology.

[62]  A. Alexandrov,et al.  Brain single-photon emission CT with HMPAO and safety of thrombolytic therapy in acute ischemic stroke. Proceedings of the meeting of the SPECT Safe Thrombolysis Study Collaborators and the members of the Brain Imaging Council of the Society of Nuclear Medicine. , 1997, Stroke.

[63]  J. Krystal,et al.  Benzodiazepine Receptor Antagonists , 1997 .

[64]  D E Kuhl,et al.  Equilibrium versus Compartmental Analysis for Assessment of the Vesicular Monoamine Transporter Using (+)-α-[11C]Dihydrotetrabenazine (DTBZ) and Positron Emission Tomography , 1997, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[65]  C. Dence,et al.  Synthesis, in vivo evaluation and PET study of a carbon-11-labeled neuronal nitric oxide synthase (nNOS) inhibitor S-methyl-L-thiocitrulline. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[66]  A. Gjedde,et al.  D2-like dopamine receptor density in Tourette syndrome measured by PET. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[67]  J. Leysen,et al.  Erratum: Initial evaluation of 123 I-5-I-R91150, a selective 5-HT(2A) ligand for single-photon emission tomography, in healthy human subjects (European Journal of Nuclear Medicine (1997) 24 (119-124)) , 1997 .

[68]  S. Kapur,et al.  The relationship between D2 receptor occupancy and plasma levels on low dose oral haloperidol: a PET study , 1997, Psychopharmacology.

[69]  A. Malhotra,et al.  Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[70]  G. Pearlson,et al.  Quantification of Neuroreceptors in the Living Human Brain: IV. Effect of Aging and Elevations of D2-Like Receptors in Schizophrenia and Bipolar Illness , 1997, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[71]  C. Meltzer,et al.  Quantification of Neuroreceptors in the Living Human Brain: III. D2-Like Dopamine Receptors: Theory, Validation, and Changes during Normal Aging , 1997, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[72]  D. E. Kuhl,et al.  Kinetic Evaluation of [11C]Dihydrotetrabenazine by Dynamic PET: Measurement of Vesicular Monoamine Transporter , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[73]  R G Blasberg,et al.  Noninvasive imaging of herpes virus thymidine kinase gene transfer and expression: a potential method for monitoring clinical gene therapy. , 1996, Cancer research.

[74]  A. Levey,et al.  Striatal dopamine, dopamine transporter, and vesicular monoamine transporter in chronic cocaine users , 1996, Annals of neurology.

[75]  J. Krystal,et al.  Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[76]  J S Fowler,et al.  PET evaluation of the dopamine system of the human brain. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[77]  V. Pickel,et al.  Ultrastructural Localization of the Vesicular Monoamine Transporter-2 in Midbrain Dopaminergic Neurons: Potential Sites for Somatodendritic Storage and Release of Dopamine , 1996, The Journal of Neuroscience.

[78]  Alan C. Evans,et al.  Dopamine transporters are markedly reduced in Lesch-Nyhan disease in vivo. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[79]  S. Kish,et al.  The Vesicular Monoamine Transporter, in Contrast to the Dopamine Transporter, Is Not Altered by Chronic Cocaine Self-Administration in the Rat , 1996, The Journal of Neuroscience.

[80]  C. Degueldre,et al.  Combined Study of Cerebral Glucose Metabolism and [11C]Methionine Accumulation in Probable Alzheimer's Disease Using Positron Emission Tomography , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[81]  K. Frey,et al.  Effects of dopaminergic drug treatments on in vivo radioligand binding to brain vesicular monoamine transporters. , 1996, Nuclear medicine and biology.

[82]  Stefan Gottschalk,et al.  Akathisia and Restless Legs , 1996 .

[83]  R. Blasberg,et al.  Imaging the expression of transfected genes in vivo. , 1995, Cancer research.

[84]  J. Hietala,et al.  Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients , 1995, The Lancet.

[85]  Eileen O. Smith,et al.  Decreased single‐photon emission computed tomographic {123I}β‐CIT striatal uptake correlates with symptom severity in parkinson's disease , 1995, Annals of neurology.

[86]  G. Pearlson,et al.  In vivo D2 dopamine receptor density in psychotic and nonpsychotic patients with bipolar disorder. , 1995, Archives of general psychiatry.

[87]  A. Grace,et al.  The tonic/phasic model of dopamine system regulation: its relevance for understanding how stimulant abuse can alter basal ganglia function. , 1995, Drug and alcohol dependence.

[88]  Zsolt Szabo,et al.  Principles of Nuclear Medicine , 1995 .

[89]  Alan C. Evans,et al.  Elevated dopa decarboxylase activity in living brain of patients with psychosis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[90]  G. Sawle,et al.  PET studies of the presynaptic and postsynaptic dopaminergic system in Tourette's syndrome. , 1994, Journal of neurology, neurosurgery, and psychiatry.

[91]  U. McCann,et al.  Dexfenfluramine and serotonin neurotoxicity: further preclinical evidence that clinical caution is indicated. , 1994, The Journal of pharmacology and experimental therapeutics.

[92]  P. Maquet,et al.  PET studies of patients with partial epilepsy: visual interpretation vs. semi‐quantification/quantification , 1994, Acta neurologica Scandinavica. Supplementum.

[93]  B. Hoffman,et al.  Expression Cloning of a Serotonin Transporter: A New Way to Study Antidepressant Drugs , 1994, Pharmacopsychiatry.

[94]  M Laruelle,et al.  Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[95]  Alan A. Wilson,et al.  Dopamine D2 receptor density estimates in schizophrenia: A positron emission tomography study with11C-N-methylspiperone , 1993, Psychiatry Research.

[96]  D. Wong,et al.  In vivo imaging of baboon and human dopamine transporters by positron emission tomography using [11C]WIN 35,428 , 1993, Synapse.

[97]  D. Doudet,et al.  Pet study of the dopamine neurotransmitter dependent tracer 6-18F-DOPA in schizophrenia , 1993, Schizophrenia Research.

[98]  J S Fowler,et al.  Striatal binding of the PET ligand 11C‐raclopride is altered by drugs that modify synaptic dopamine levels , 1993, Synapse.

[99]  G. Sedvall,et al.  Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. , 1992, Archives of general psychiatry.

[100]  H N Wagner,et al.  In vivo imaging of dopamine reuptake sites in the primate brain using single photon emission computed tomography (SPECT) and iodine‐123 labeled RTI‐55 , 1992, Synapse.

[101]  D. Wong,et al.  Effects of endogenous dopamine on kinetics of [3H]N‐methylspiperone and [3H]raclopride binding in the rat brain , 1991, Synapse.

[102]  S. Stone-Elander,et al.  D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride. , 1990, Archives of general psychiatry.

[103]  J. Links,et al.  In Vivo Measurement of Dopamine Receptors in Human Brain by Positron Emission Tomography Age and Sex Differences a , 1988, Annals of the New York Academy of Sciences.

[104]  G. Pearlson,et al.  Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. , 1986, Science.

[105]  D. Comar,et al.  [76Br]bromolisuride: a new tool for quantitative in vivo imaging of D-2 dopamine receptors. , 1986, European journal of pharmacology.

[106]  J M Links,et al.  Quantification of Neuroreceptors in the Living Human Brain. II. Inhibition Studies of Receptor Density and Affinity , 1986, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[107]  A. Gjedde,et al.  Quantification of Neuroreceptors in the Living Human Brain. I. Irreversible Binding of Ligands , 1986, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[108]  M. Folstein,et al.  EFFECTS OF AGE ON DOPAMINE AND SEROTONIN RECEPTORS MEASURED BY POSITRON TOMOGRAPHY IN THE LIVING HUMAN BRAIN , 1984, Science.

[109]  Jonathan M. Links,et al.  Imaging dopamine receptors in the human brain by positron tomography , 1983 .

[110]  L. Iversen,et al.  DOPAMINE RECEPTORS AND SCHIZOPHRENIA: DRUG EFFECT OR ILLNESS? , 1980, The Lancet.

[111]  S. Snyder,et al.  Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain. , 1977, Science.

[112]  R. Duman,et al.  Administration of a cAMP Phosphodiesterase 4 Inhibitor Enhances Antidepressant-Induction of BDNF mRNA in Rat Hippocampus , 2000, Neuropsychopharmacology.

[113]  J. Seibyl,et al.  Rapid Communication Age-related decline in central serotonin transporter availability with ( 123 I)b-CIT SPECT < , 2000 .

[114]  M. Ernst,et al.  High presynaptic dopaminergic activity in children with Tourette's disorder. , 1999, Journal of the American Academy of Child and Adolescent Psychiatry.

[115]  M. Kilbourn,et al.  Synthesis and evaluation of (E)-(3-[I-125]iodoprop-2-enyl) ether derivatives of α- and β-dihydrotetrabenazine as possible radioligands for the neuronal vesicular monoamine transporter (VMAT2) , 1999 .

[116]  A. Grace,et al.  The modulation of corticoaccumbens transmission by limbic afferents and dopamine: a model for the pathophysiology of schizophrenia. , 1998, Advances in pharmacology.

[117]  Judith M. Rumsey,et al.  Neuroimaging : a window to the neurological foundations of learning and behavior in children , 1996 .

[118]  G. Pearlson,et al.  Quantitative D2 dopamine receptor PET and structural MRI changes in late-onset schizophrenia. , 1993, Schizophrenia bulletin.

[119]  D. Wong,et al.  Dopamine transporter: biochemistry, pharmacology and imaging. , 1990, European neurology.

[120]  P. Seeman,et al.  Endogenous dopamine lowers the dopamine D2 receptor density as measured by [3H]raclopride: Implications for positron emission tomography of the human brain , 1989, Synapse.

[121]  John H. Krystal,et al.  Positron emission tomography and autoradiography: Principles and applications for the brain and heart , 1985 .

[122]  H. Hansen,et al.  Letter: Ectopic production of calcitonin. , 1973, Lancet.